MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 12, 2004; DOI: 10.1124/mol.104.004309


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.004309v1
mol.104.004309v2
mol.104.004309v3
66/5/1213    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nanamori, M.
Right arrow Articles by Ye, R. D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nanamori, M.
Right arrow Articles by Ye, R. D


Received for publication July 7, 2004.
Revised August 10, 2004.
Accepted for publication August 12, 2004.

A novel nonpeptide ligand for formyl peptide receptor-like 1

Masakatsu Nanamori 1, Xiyuan Cheng 2, Jianghua Mei 2, Hairong Sang 1, Yunxia Xuan 2, Caihong Zou 2, Ming-Wei Wang 2, Richard D Ye 1*

1 University of Illinois at Chicago 2 The National Center for Drug Screening, Shanghai

* Address correspondence to: E-mail: yer{at}uic.edu

Abstract

Formyl peptide receptor-like 1 (FPRL1) is a G protein-coupled receptor that binds natural and synthetic peptides as well as lipoxin A4 and mediates important biological functions. To facilitate its pharmacological characterization, we screened a compound library and identified a substituted quinazolinone (Quin-C1, 4-butoxy-N-[2-(4-methoxy-phenyl)-4-oxo-1,4-dihydro-2H-quinazolin-3-yl]-benzamide) as a ligand for FPRL1. Quin-C1 induces chemotaxis and secretion of beta-glucuronidase in peripheral blood neutrophils with a potency of approximately 1/1,000 of that of the peptide agonist WKYMVm. In studies using transfected rat basophilic leukemia (RBL) cell lines expressing either FPR or FPRL1, Quin-C1 induced enzyme release from RBL-FPRL1 but not RBL-FPR cells. Likewise, Quin-C1 selectively stimulates calcium mobilization in RBL-FPRL1 cells, a response that was markedly inhibited by pertussis toxin. Quin-C1 also stimulates phosphorylation of extracellular signal-regulated protein kinases 1 and 2, and induces internalization of an FPRL1 fused to green fluorescent protein. In degranulation assays, both the FPRL1-selective peptide agonist MMK1 and Quin-C1 exhibited lower efficacy and potency than WKYMVm, with EC50 values of 7.17 x 10-8 M and 1.88 x 10-6 M, respectively, as compared to the EC50 value for WKYMVm (2.29 x 10-8 M). However, Quin-C1 did not induce neutrophil superoxide generation at up to 100 micromolar concentration. Based on these results, we conclude that Quin-C1 is a novel nonpeptide ligand that binds to FPRL1 and selectively stimulates FPRL1-mediated functions. Quin-C1 is a prototype of substituted quinazolinones based on which further structural modifications may be made to improve its efficacy and potency for FPRL1.


Key words: Chemotactic peptides, Gi family, Combinatorial chemistry, Receptor binding studies, Receptor-mediated, Leukocytes/Mast cells





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics